MiMedx Group, Inc. (NASDAQ:MDXG) Insider Sells $17,732.40 in Stock

MiMedx Group, Inc. (NASDAQ:MDXG) insider Kimberly Maersk-Moller sold 2,111 shares of MiMedx Group stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $8.40, for a total value of $17,732.40. Following the completion of the transaction, the insider now directly owns 265,271 shares of the company’s stock, valued at $2,228,276.40. This represents a 0.79 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

MiMedx Group Stock Performance

Shares of NASDAQ:MDXG opened at $7.89 on Friday. The stock has a market capitalization of $1.16 billion, a P/E ratio of 14.35 and a beta of 1.97. MiMedx Group, Inc. has a 1-year low of $5.47 and a 1-year high of $10.14. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. The business has a 50-day moving average price of $8.63 and a two-hundred day moving average price of $7.75.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, hitting the consensus estimate of $0.07. The firm had revenue of $92.91 million during the quarter, compared to analysts’ expectations of $89.42 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. Equities analysts predict that MiMedx Group, Inc. will post 0.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on MDXG. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $13.00 price target on shares of MiMedx Group in a report on Thursday, February 27th. StockNews.com cut MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Friday, November 8th.

Institutional Trading of MiMedx Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in MDXG. First Light Asset Management LLC bought a new stake in MiMedx Group during the 4th quarter worth about $32,168,000. Norges Bank bought a new stake in MiMedx Group during the 4th quarter worth about $4,020,000. JPMorgan Chase & Co. grew its position in shares of MiMedx Group by 133.1% during the 4th quarter. JPMorgan Chase & Co. now owns 693,106 shares of the company’s stock worth $6,668,000 after buying an additional 395,739 shares during the period. Meros Investment Management LP acquired a new position in shares of MiMedx Group during the 4th quarter worth about $3,801,000. Finally, Arrowstreet Capital Limited Partnership grew its position in shares of MiMedx Group by 484.2% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 362,481 shares of the company’s stock worth $3,487,000 after buying an additional 300,433 shares during the period. 79.15% of the stock is owned by institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.